Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 17/20 | 0.91 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.91 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL6756474 | 0.98 | FDPS (0.87) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL8734225 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL6856868 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1115700 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL140618 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4279497 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5974139 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL140619 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL192828 | 0.95 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL579003 | 0.95 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112316153-B | Antitumor pharmaceutical composition and application thereof | 中山大学附属第七医院(深圳) | 2023-08-25 | — | — | CN | claimed |
| CN-114349786-B | Alam calcium phosphonate super-long nanowire and preparation method and application thereof | 中国科学院上海硅酸盐研究所 | 2023-07-11 | — | — | CN | claimed |
| CN-114349786-A | Alendronate calcium ultralong nanowire and preparation method and application thereof | 中国科学院上海硅酸盐研究所 | 2022-04-15 | — | — | CN | claimed |
| CN-112707934-A | Alendronate calcium complex and preparation method thereof | 华南理工大学 | 2021-04-27 | — | — | CN | claimed |
| CN-112316153-A | Anti-tumor pharmaceutical composition and application thereof | 中山大学附属第七医院(深圳) | 2021-02-05 | — | — | CN | claimed |
| US-8974801-B2 | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate | AMPHASTAR PHARMACEUTICALS INC. (US) | 2015-03-10 | — | — | US | claimed |
| US-20080011613-A1 | Method of electrolytically depositing a pharmaceutical coating onto a conductive osteal implant | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2008-01-17 | — | — | US | claimed |
| WO-2006007730-A1 | METHOD OF ELECTROLYTICALLY DEPOSITING A PHARMACEUTICAL COATING ONTO A CONDUCTIVE OSTEAL IMPLANT | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2006-01-26 | — | — | WO | claimed |
| EP-0831756-A1 | BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES | Merck & Co., Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039107-A1 | BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | claimed |
| CN-112316153-B | Antitumor pharmaceutical composition and application thereof | 中山大学附属第七医院(深圳) | 2023-08-25 | — | — | CN | disclosed |
| CN-114349786-B | Alam calcium phosphonate super-long nanowire and preparation method and application thereof | 中国科学院上海硅酸盐研究所 | 2023-07-11 | — | — | CN | disclosed |
| CN-114349786-B | Alam calcium phosphonate super-long nanowire and preparation method and application thereof | 中国科学院上海硅酸盐研究所 | 2023-07-11 | — | — | CN | disclosed |
| CN-111544655-B | Bisphosphonate type self-coagulation composite bone graft and preparation method thereof | 中鼎凯瑞科技成都有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114349786-A | Alendronate calcium ultralong nanowire and preparation method and application thereof | 中国科学院上海硅酸盐研究所 | 2022-04-15 | — | — | CN | disclosed |
| US-5589691-A | Process for recovery and recycle of methanesulfonic acid and phosphorous acid | MERCK & CO., INC. (US) | 1996-12-31 | — | — | US | disclosed |
| WO-1996039107-A1 | BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995033755-A1 | PROCESS FOR REMOVING WASTE POx, ALENDRONATE AND ITS BY-PRODUCTS | MERCK & CO., INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995033756-A1 | PROCESS FOR RECOVERY AND RECYCLE OF METHANESULFONIC ACID AND PHOSPHOROUS ACID | MERCK & CO., INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5449819-A | Process for removing waste pox, alendronate and its by products | MERCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080011613-A1 | Method of electrolytically depositing a pharmaceutical coating onto a conductive osteal implant | SOST, CACNA2D1, CACNA2D3 | FDPS 2307/4885PDE3A 789/4885LMNA 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.